Request For Re-Examination Of Ceftobiprole Submitted To CHMP

Main Category: Infectious Diseases / Bacteria / Viruses
Also Included In: Dermatology
Article Date: 11 Mar 2010 - 13:00 PDT

Current ratings for:
'Request For Re-Examination Of Ceftobiprole Submitted To CHMP'

Patient / Public:not yet rated

Healthcare Prof:not yet rated


Basilea Pharmaceutica Ltd. (SWISS: BSLN) announces that the Applicant Janssen-Cilag International NV (Janssen- Cilag), a Johnson & Johnson company, has submitted a request for re-examination of the negative opinion by the European Committee for Medicinal Products for Human Use (CHMP) on the Marketing Authorization Application (MAA) for ceftobiprole for the treatment of complicated skin and soft tissue infections (cSSTI).

On February 18, 2010, the CHMP adopted a negative opinion on the MAA for ceftobiprole for the treatment of cSSTI. The Applicant Janssen-Cilag has given written notice to the Agency that it requests a re-examination of the negative opinion under standard procedures. According to current CHMP guidelines, a final opinion on the re-examination could be issued by the Agency within four to five months.

Source
Basilea Pharmaceutica Ltd.

Article adapted by Medical News Today from original press release.
Visit our infectious diseases / bacteria / viruses section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Basilea Pharmaceutica Ltd. "Request For Re-Examination Of Ceftobiprole Submitted To CHMP." Medical News Today. MediLexicon, Intl., 11 Mar. 2010. Web.
25 May. 2012. <http://www.medicalnewstoday.com/releases/181979.php>
APA
Basilea Pharmaceutica Ltd. (2010, March 11). "Request For Re-Examination Of Ceftobiprole Submitted To CHMP." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/181979.php.

Please note: If no author information is provided, the source is cited instead.


Add Your Opinion On This Article

'Request For Re-Examination Of Ceftobiprole Submitted To CHMP'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Your Name:*
E-mail Address:*
Your Opinion Title:*
Opinion:*
This is to help prevent SPAM submissions. Please enter the words exactly as they appear, including capital letters and punctuation.*

* Fields marked with a * need to be filled in before you hit the submit button.

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.


Infectious Diseases / Bacteria / Viruses

Most Popular Articles



Follow Our Infectious Diseases News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Infectious Diseases / Bacteria / Viruses Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »